Should I buy Henry Schein (HSIC) stock or is it too late?

Henry Schein · Health Care · price $90

See the full Henry Schein (HSIC) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $85 (-5.8 %), call made on July 10, 2026, maturing on July 10, 2027 (49 d ago).

The 6 reliable analysts $97.50+8.0 %

The 3 other firms $82-9.2 %

How to read it: the 6 reliable firms are not filtered by optimism — 5 aim above the price, 1 below, hence their $97.50 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Henry Schein

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Piper Sandler	71 %	+3.3 %	7	$95 +5%
Baird	40 %	+2.0 %	5	$100 +11%
Barrington Research	47 %	+1.8 %	15	$97 +7%
Morgan Stanley	71 %	-2.1 %	7	$64 -29%
Credit Suisse	40 %	-2.1 %	5	—

In short — Should you invest in Henry Schein? Is it too late, still worth it? Analysts are fairly positive (56% buy, median target $94, i.e. +4%), and the most reliable on HSIC targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

The most reliable firm on HSIC, Piper Sandler (71% hit rate, 7 scored calls), targets $95 (call made on July 29, 2026, maturing on July 29, 2027) (+5%) in its most recent call.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 9 ratings, 3 are neutral and 1 is a sell.
Limited upside: the median target is only +4% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on HSIC

Median target $94 (+4%) · 9 ratings · Hold consensus

Strong Buy00%

Buy556%

Hold333%

Sell111%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Henry Schein now?

We won't decide for you. The facts: 56% of analysts rate it a buy, median target $94 (+4%), and Piper Sandler (most reliable on HSIC, 71%) targets $95. Weigh that against valuation (P/E ~26). This is not personalized advice.

Is it too late to invest in Henry Schein?

Not according to analysts: the median target ($94) is still +4% above the current price ($90) (most reliable on HSIC: Piper Sandler, 71%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Henry Schein still worth investing in?

It depends on the gap between the price ($90) and its estimated value: analysts target $94 on median (+4%), with 56% buys (most reliable on HSIC: Piper Sandler, 71%). Cross-check with their real reliability on HSIC and the cautions above. Information, not advice.

What's the main risk in buying HSIC?

The consensus is not unanimous: of 9 ratings, 3 are neutral and 1 is a sell.

→ Go deeper: the full Henry Schein profile (consensus, analyst reliability, price target, performance).